Fermenta Biotech is currently trading at Rs. 637.05, up by 34.80 points or 5.78% from its previous closing of Rs. 602.25 on the BSE.
The scrip opened at Rs. 615.00 and has touched a high and low of Rs. 648.00 and Rs. 610.00 respectively. So far 6772 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 5 has touched a 52 week high of Rs. 1125.00 on 10-Jan-2019 and a 52 week low of Rs. 583.00 on 14-Nov-2019.
Last one week high and low of the scrip stood at Rs. 698.00 and Rs. 583.00 respectively. The current market cap of the company is Rs. 623.99 crore.
The promoters holding in the company stood at 63.15%, while Institutions and Non-Institutions held 0.55% and 36.30% respectively.
Fermenta Biotech has opened a wholly owned subsidiary in Germany, to be closer to its customers. This subsidiary would also manufacture value-added products like D3 500 Feed grade, D3 100 Food grade etc. in Europe through third parties. These value-added products would typically be new variants wherein the company would utilise third party resources in terms of plant, equipment etc. This will strengthen its position in terms of quality, reach and tap into new customers without any additional CAPEX.
Fermenta Biotech is manufacturer and supplier of Vitamin D3 (Cholecalciferol), Leading supplier of Penicillin G Amidase, CAL B Lipase, Polymer Supports and enzyme technologies for beta lactams and Bio-Enzymes for Environmental Solutions waste water management and Lake & pond bioremediation.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: